|
|
Article: GPC Biotech Shares Jump On Prostate Cancer Study Results.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BioWorld International Correspondent
Shares in GPC Biotech AG surged Monday on news that the company's lead compound, the orally available platinum analogue satraplatin, attained the primary endpoint in a Phase III registration trial of the compound as a second-line therapy in hormone refractory prostate cancer.
The stock (Frankfurt:GPC) peaked at C16.70 (US$21.30) during trading on the Frankfurt Stock Exchange, and closed at C14.70, up 36.4 percent from Friday's close of C10.78.
Its European marketing partner, Boulder, Colo.-based Pharmion Corp., also climbed strongly on the news, with shares (NASDAQ:PHRM) jumping $3.60, or 20 percent to close ...